Wall Street expects GE HealthCare Technologies to report Q2 2026 revenue of $4.96 billion and earnings per share of $1.04, with the stock trading at $82.45 compared to a consensus price target of $101.50.
Investors are primarily focused on the recovery of the China market, looking for signs that demand for medical imaging equipment is rebounding following previous regulatory headwinds.
Recent performance has been bolstered by a strong order backlog and the successful integration of AI-driven diagnostic tools, which analysts believe will drive margin expansion. Market participants are also monitoring the company's progress on debt reduction and its ability to maintain mid-single-digit organic growth across its core Imaging and Ultrasound segments.